focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: European stocks edge higher in cautious trade

Thu, 06th Apr 2023 08:37

(Alliance News) - Stock prices in London opened higher on Thursday, but sentiment was fragile amid fears of an economic slowdown in the US, and heightened geopolitical tensions.

The FTSE 100 index opened up 28.70 points, 0.4%, at 7,691.64. The FTSE 250 was up 38.53 points, 0.2%, at 18,639.95, and the AIM All-Share was up 1.81 points, 0.2%, at 805.50.

The Cboe UK 100 was up 0.5% at 769.72, the Cboe UK 250 was up 0.6% at 16,231.96, and the Cboe Small Companies was down 0.3% at 13,157.49.

In European equities, the CAC 40 in Paris and the DAX 40 in Frankfurt were each up 0.1%.

Financial markets in the London, Paris, Frankfurt and New York will be closed on Friday to mark Good Friday. However, the US jobs report will still be reported at 1330 BST on Friday.

UK and European markets will remain closed on Easter Monday, while New York re-opens.

Annual growth in UK house prices weakened to levels not seen since October 2019, according to data from Halifax. According to the mortgage lender, average house prices edged up 0.8% in March on a monthly basis. Growth slowed from a 1.2% climb in February. Annually, growth in house prices slowed to 1.6% in March, from the 2.1% climb seen in each of the previous three months.

In London, residential property market slowdown fears hit shares in housebuilder Barratt, down 1.8%, and estate agent Savills, shedding 3.6%.

The dollar was slightly stronger in early exchanges.

Sterling was quoted at USD1.2461 early Thursday, lower than USD1.2471 at the London equities close on Wednesday. The euro traded at USD1.0903, down from USD1.0919. Against the yen, the dollar was quoted at JPY131.36, up versus JPY130.94.

In the US on Wednesday, Wall Street ended mixed, with the Dow Jones Industrial Average ending up 0.2%, the S&P 500 down 0.3% and the Nasdaq Composite down 0.3%.

"A number of US releases suggested that the economy is beginning to wilt under the pressure of the Federal Reserve's aggressive hiking policy, with attention now turning to the scale of a recession, rather than whether one will happen," said interactive investor analyst Richard Hunter.

On Wednesday, survey data from the Institute for Supply Management indicated that the slowdown in the US services sector was faster than expected. The ISM services PMI registered 51.2 in March, its third consecutive month of growth, but down from 55.1 points in February. Markets had expected the reading to dip to 54.5 points, according to FXStreet.

Meanwhile, in Asia on Thursday, the Nikkei 225 index in Tokyo closed down 1.1%. The S&P/ASX 200 in Sydney closed down 0.3%. In China, the Shanghai Composite was marginally lower, while the Hang Seng index in Hong Kong was marginally higher.

Sentiment was unsteady as geopolitical tensions between the world's two largest economies escalated. China sent warships through waters around Taiwan on Thursday as it vowed a "resolute response" to the island's president meeting US House Speaker Kevin McCarthy.

"The fractious relationship between the world's two largest economies is never far from investors' minds, and the latest development was enough to unsettle sentiment, despite some stronger economic readings, most notably a further accelerating services sector in China," ii's Hunter commented.

China's services sector continued to rebound in March, according to the latest survey data on Thursday.

The Caixin services purchasing managers' index rose to 57.8 points in March from 55.0 in February, rising further above the 50-point mark that separates expansion from contraction. It shows a sharp acceleration in the pace of growth.

It was the strongest expansion seen since November 2020, and the third consecutive month of growth.

Meanwhile, developments in Middle Eastern relations may also unnerve the US.

Top diplomats from Middle East rivals Iran and Saudi Arabia met in Beijing on Thursday, pledging to work together to bring "security and stability" to their turbulent region following a surprise China-brokered deal.

In a joint statement released after talks between Iranian Foreign Minister Hossein Amir-Abdollahian and Saudi counterpart Prince Faisal bin Farhan, the two sides vowed to continue to work together to improve ties.

"The oil-rich kingdom has restricted oil output twice against the wishes of the United States, and it has forged goodwill with its neighbouring country, Iran—a country with whom the Saudis have long been at odds," said Zaye Capital Markets' Naem Aslam.

"This predicament has led traders to believe that they need to use extreme caution when deciding which asset class to support," he added.

Brent oil was trading at USD84.56 a barrel early Thursday, up from USD84.48 late Wednesday. It was up sharply from USD79.14 at the market close on Friday, before the surprise production cut announcement from Opec+ last weekend.

In the FTSE 100, Shell rose 2.0% in early trading.

The oil major said it expects a rise in Integrated Gas production in the first quarter of 2023, though it predicted an adjusted corporate loss on a tax hit.

Shell predicted an adjusted loss in its corporate segment between USD900 million and USD1.2 billion, widening from USD600 million in the fourth quarter of 2022. The outcome "includes one-off tax charges", the company said.

It expects Integrated Gas adjusted earnings pre-tax depreciation between USD1.2 and USD1.6 billion, compared to USD1.4 billion in the fourth quarter.

Upstream adjusted earnings are expected between USD2.8 billion to US3.1 billion, compared to USD2.9 billion. For Integrated Gas, it forecast production between 930,000-970,000 barrels of oil equivalent, up from 917,000 boe in the fourth quarter. Upstream production volumes are expected to be within a similar range to the previous quarter, between 1.8 million and 1.9 million boe per day, compared to 1.85 million in the fourth quarter.

Astrazeneca rose 0.9%, on news UK's NHS has approved the use of one of its drugs, which could benefit hundreds of patients with breast cancer and prostate cancer.

Men with advanced prostate cancer and women with HER2-negative early breast cancer who are at high risk of the disease returning will be able to access olaparib through the NHS in England. The decision has been overwhelmingly welcomed, with praise from cancer charities and scientists.

Reckitt Benckinser, ConvaTec and Rentokil fell by 1.9%, 1.2% and 1.3% respectively, as the stocks went ex-dividend.

Gold was quoted at USD2,013.40 an ounce, lower than USD2,021.30, but also up sharply from USD1,979.05 last Friday.

In the FTSE 250, Ferrexpo rose 3.5%.

The iron ore pellet maker updated on its production in the first quarter. Total iron ore pellet production doubled to 901,000 tonnes from the 420,000 tonnes in the fourth quarter. The rise was mostly down to the improvement in electricity supply to its operations in Ukraine, the firm said. This enabled Ferrexpo to restart a second pelletiser line in late February.

Among London's small-caps, Robert Walters fell 3.5%.

The recruitment firm reported a "slower start" to 2023. Net fee income in the first quarter rose 4% year-on-year to GBP102.4 million. It grew 16% in Europe and 18% in Other Internation, helping to offset a 9% decline in the UK and a 1% fall in Asia Pacific. However, on a constant currency basis, net fee income was flat.

"Uncertain global macroeconomic conditions continued to impact recruitment activity levels across a number of the group's markets and disciplines," the firm said.

Robert Walters pointed to the "relatively robust" market fundamentals such as vacancy levels and salary inflation, as well as a global shortage of qualified professionals. It expects the rebound in the Chinese economy, easing inflation and the stabilisation of the technology sector to boost the global outlook.

Still to come on Thursday's economic calendar, there's a UK construction PMI print at 0930 BST. The US weekly unemployment insurance claims will be released at 1330 BST

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.